<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794025</url>
  </required_header>
  <id_info>
    <org_study_id>K2010-001-01</org_study_id>
    <nct_id>NCT02794025</nct_id>
  </id_info>
  <brief_title>The Effect of Esmolol on Clinical Prognosis of Patients With Severe Sepsis</brief_title>
  <official_title>The Effect of Esmolol on Tissue Perfusion and Clinical Prognosis of Patients With Severe Sepsis: a Prospective Cohort Study .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Provincial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the effect of esmolol on hemodynamic
      parameters,tissue perfusion and the clinical prognosis of patients with severe sepsis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      enrollment:151 patients

      Inclusion criteria: (1) age &gt; 18 years; (2) severe sepsis (acute organ dysfunction secondary
      to infection )diagnosis according to Campaign to Save Septic Patients: 2008 Treatment
      Guidelines for Severe Sepsis and Septic Shock, who (3) mechanical ventilation via
      endotracheal intubation with a tidal volume of 6 mL/kg; and (4) satisfactory sedation and
      analgesic treatment, with HR &gt; 100 bpm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The survival time of patients more than 28 days is defined as survival. The survival time of patients less than 28 days is defined as death.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>esmolol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm &lt; HR &lt; 100 bpm within 72 hours).
Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.</description>
    <arm_group_label>esmolol group</arm_group_label>
    <other_name>Î²-blockers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>natural saline</intervention_name>
    <description>Control group also received natural saline via a micro pump,</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years;

          -  severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to
             Campaign to Save Septic Patients: 2008 Treatment Guidelines for Severe Sepsis and
             Septic Shock,

          -  mechanical ventilation via endotracheal intubation with a tidal volume of 6 mL/kg;

          -  satisfactory sedation and analgesic treatment, with HR &gt; 100 bpm.

        Exclusion Criteria:

          -  pre-existing cardiac dysfunction, valvular heart disease, high-degree atrioventricular
             block;

          -  acute or chronic pulmonary heart disease;

          -  a history of serious asthma;

          -  chronic renal insufficiency;

          -  cancer, autoimmune diseases, or contraindications for placement of deep venous
             catheter;

          -  insulin-dependent diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongguo Yu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fujian Provincial Hospital</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Xiuling Shang</investigator_full_name>
    <investigator_title>the ethic committee of Fujian Provincial Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>151 patients with severe sepsis were selected and divided into the esmolol group (n = 75) or the control group (n = 76)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

